1 – 10 of 39
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis : results from five Nordic biologics registries
(
- Contribution to journal › Article
-
Mark
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis : Results From the European Spondyloarthritis Research Collaboration Network
2023) In Arthritis and Rheumatology(
- Contribution to journal › Article
-
Mark
Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis : Results from the EuroSpA Research Collaboration Network
(
- Contribution to journal › Article
- 2022
-
Mark
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
(
- Contribution to journal › Article
-
Mark
Comment on : Incidence of extra-articular manifestations in AS, PsA and undifferentiated SpA: Results from a national register-based cohort study. Reply
(
- Contribution to journal › Letter
-
Mark
Lifestyle Factors and Disease Activity Over Time in Early Axial Spondyloarthritis : The SPondyloArthritis Caught Early (SPACE) Cohort
(
- Contribution to journal › Article
-
Mark
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis : Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses
(
- Contribution to journal › Article
-
Mark
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration
(
- Contribution to journal › Article
- 2021
-
Mark
Humpback Whale (Megaptera novaeangliae) Song on a Subarctic Feeding Ground
(
- Contribution to journal › Article
-
Mark
Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care : Does the choice of biological therapy matter?
(
- Contribution to journal › Article